The federal Department of Health has announced recipients of more that $1 billion for small biotech companies across the country. Under the Affordable Care Act, nearly 3,000 small biotechs in 47 states received grants to develop therapies, support jobs, and increase U.S. competitiveness. The money covers up to half the cost of qualifying biomedical research and was given only to firms with fewer than 250 employees.
In New Jersey, nearly $52 million will go to support 227 projects. Twenty-one of those projects belong to firms in the U.S. 1 area, with many based at the Technology Center of NJ in North Brunswick and at Deer Park Drive at the Princeton Corporate Plaza:
Ad 4-Pharma, 7 Deer Park Drive, Suite D, Monmouth Junction 08852; 732-274-2303. J.P. Errico, owner.
Identifies compounds targeting oncology and cardiovascular disorders. Received $716,810 for various molecule compounds
Adavaxis (ADXS), 675 Route 1 South, Technology Center of New Jersey, North Brunswick 08902; 732-545-1590; fax, 732-545-1084. Thomas Moore, CEO. www.adavaxis.com
Develops live Listeria monocytogenes vaccines. Received $244,479.24 for a live attenuated cancer vaccine
Agennix (GPCB), 101 College Road East, Princeton 08540; 609-524-1000; fax, 609-524-1050. Freidrich von Bohlen und Hallbach, CEO. www.agennix.com
Focused mainly on the development and commercialization of anti-cancer drugs. Received $244,479,25 for a low-dose contraceptive patch.
Amicus Therapeutics, 5 Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury 08512; 609-662-2000; fax, 609-662-2001. John F. Crowley, CEO. www.amicustherapeutics.com
Developer of novel therapies to treat genetic diseases, based on chaperone technology. Received $2.3 million for research into Alzheimer’s, Parkinson’s, and Fabry diseases.
Celator Pharmaceuticals, 303 B College Road East, Princeton 08540; 609-243-0123; fax, 609-243-0202. Scott Jackson, CEO. www.celatorpharma.com
R&D of oncology drugs. Received 244,279.25 to develop its liposome formula.
Chromocell Corporation, 685 Route 1 South, Technology Center of New Jersey, North Brunswick 08902; 732-565-1113; fax, 732-565-1183. Christian Kopfli, CEO. www.chromocell.com
Drugs for pain relief, anxiety, and respiratory disorders. Received $244,479.25 to develop antagonists for chronic pain.
CytoSorbents, 7 Deer Park Drive, Suite K, Monmouth Junction 08852; 732-329-8885; fax, 732-329-8650. Phil Chan, CEO. www.cytosorbents.com
Devices that remove toxins from the blood. Received $488,958.50 to develop anti-inflammatory therapeutics for use with life-threatening diseases.
Derma Sciences Inc. (DSCIOB), 214 Carnegie Center, Suite 300, Princeton 08540; 609-514-4744; fax, 609-514-0502. Edward J. Quilty, CEO. www.dermasciences.com
Developer of wound management and skin care products. Received $244,479.25 for its clinical development program.
MicroDose Therapeutx, 4262 Route 1 North, Monmouth Junction 08852; 732-355-2100. Anand V. Gumaste, CEO. www.mdtx.com
Developer of drug delivery devices, particularly inhalers. Received $977,917 for various respiratory and gastric drugs.
Orthobond, 675 Route 1 South, Technology Center of NJ, North Brunswick 08902; 732-729-6235; fax, 732-745-7470. Marc Burel, general manager. www.orthobond.com
Bio/inorganic interface technology for orthopedics. Received $488,958.50 to develop implantable medical devices.
Palatin Technologies Inc. (PTN), 4C Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury 08512; 609-495-2200; fax, 609-495-2201. Carl Spana PhD, president & CEO. www.palatin.com
Developer of products for sexual dysfunction and appendicitis detection. Received $1.2 million to develop medications for obesity, sexual dysfunction, and asthma.
PharmaSeq Inc., 11 Deer Park Drive, Princeton Corporate Plaza, Suite 104, Monmouth Junction 08852; 732-355-0100; fax, 732-355-0102. Wlodek Mandecki, president. www.pharmaseq.com
Maker of instrumentation for diagnostics and assays for drug discovery; also laser light-powered microchips for non-biotech applications. Received $449,824.75 to develop various cancer-related therapies.
Pharmasset Inc., 303-A College Road, Princeton 08540; 609-613-4100; fax, 609-613-4150. P. Schaefer Price, CEO. www.pharmasset.com
Developer of oral therapeutics for treatment of viral infections. Received $488,958.50 for various oral therapy drugs.
Phytomedics Inc., 1085 Cranbury-South River Road, Suite 8, Jamesburg 08831-3410; 609-655-0715; fax, 609-655-0552. Bertold Fridlender, CEO. www.phytomedics.com
Researches plant sources for new drugs and supplements and for synthesis of existing drugs. Received $244,479.25 to develop rheumatoid arthritis treatments.
Redpoint Bio Corporation (RPBC), 7 Graphics Drive, Ewing 08628; 609-637-9700; fax, 609-637-0126. F. Raymond Salemme, CEO. www.redpointbio.com
Conducts research in molecular biology of taste signaling for the flavor industries. Received $244,479.25 for diabetes drug research.
Senesco Technologies Inc. (SNT), 303 George Street, Suite 420, New Brunswick 08901; 732-296-8400; fax, 732-296-9292. Leslie Browne, president and CEO. www.senesco.com
Developer of gene technology to extend the shelf-life of produce, regulating the onset of cell death. Received $244,479.24 to develop therapeutics for multiple myeloma.
Signum Biosciences, 7 Deer Park Drive, Suite H, Monmouth Junction 08852; 732-329-6344; fax, 732-329-8344. Maxwell Stock, vice president. www.signumbiosciences.com
Received $978,070 to develop treatments for acne, Alzheimer’s disease, Parkinson’s disease, and rosacea.
Symphogen Inc., 116 Village Boulevard, Suite 200, Princeton 08540; 609-951-2295. Kristen Drejer, CEO. www.symphogen.com
Antibody therapeutics. Received $488,958.50 to develop cancer therapies.
Transave Inc., 11 Deer Park Drive, Suite 117, Monmouth Junction 08852-1923; 732-438-9434; fax, 732-438-9435. Tim Whitten, CEO. www.transaveinc.com
Drug delivery systems for lung diseases. Received $488,958 to develop medicines for bronchial illness and muscular dystrophy.
TyRx Pharma Inc., 1 Deer Park Drive, Suite G, Monmouth Junction 08852; 732-246-8676; fax, 732-246-8677. Robert White, CEO. www.TyrxPharma.com
Developer of pharmacologically active medical devices that enhance patient care in the treatment of acute and chronic disease. Received $488,958.48 to develop post-surgery infection control therapeutics.
WellGen Inc., 675 Route 1 South, Technology Center of NJ, North Brunswick 08902-8520; 732-565-3890; fax, 732-565-3896. Roderick Carter, M.D., CEO. www.wellgen.com
Food, dietary, and therapeutic applications. Received $244,479.24 to develop nutrigenomic treatments for chronic diseases.
 |